 | |
| Clinical data | |
|---|---|
| Other names | BMS-234303; BMS234303 |
| Routes of administration | Topical[1] |
| Drug class | ATP-sensitivepotassium channel opener;Vasodilator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H19N5 |
| Molar mass | 269.352 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Naminidil (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code nameBMS-234303) is anATP-sensitivepotassium channel opener withvasodilator activity which was under development as atopical medication for the treatment ofandrogenic alopecia (pattern hair loss) but was never marketed.[2][3][1] The drug was under development byBristol-Myers Squibb and reachedphase 2clinical trials by 2001.[2] One of the phase 2 trials compared naminidil, minoxidil, andplacebo for alopecia.[1] However, no results of the study appear to have been made available.[1] Development of naminidil was discontinued by 2008.[2] In terms ofchemical structure, naminidil is aguanidinederivative and is structurally distinct fromminoxidil.[2][4]
 | Thisdermatologicdrug article is astub. You can help Wikipedia byadding missing information. |
